MONTREAL, QUEBEC--(Marketwire - February 28, 2008) - Mistral Pharma Inc. (TSX VENTURE: MIP) (the “Corporation”, “Mistral”) announces today its financial results and review of operating highlights for the third quarter and for the nine-month period ended December 31, 2007. “The highlights of Mistral’s third quarter were the successful pilot clinical trial of our MIST-BO4 product, and of course, the launch of our first approved product Instillagel®", said Bertrand Bolduc, the Corporation’s President & CEO.
